Are there Skyrizi (risankizumab) biosimilars expected to launch by 2026?
This depends on which part of the pipeline you mean: biosimilar development (clinical trials), regulatory approval, and then commercial launch. The provided information here does not include specific Skyrizi biosimilar developers, trial milestones, or projected approval/launch timelines for 2026, so a precise “pipeline through 2026” forecast can’t be confirmed.
Which biosimilar candidates are in development for risankizumab?
A 2026-focused pipeline view normally lists (1) the company sponsoring the biosimilar, (2) whether it is in phase 1/2 or phase 3, and (3) the expected regulatory path (e.g., EMA or FDA). The information available in this prompt does not include those candidate names or study stages, so I can’t reliably enumerate the current risankizumab biosimilar development pipeline.
What milestones typically drive a 2026 biosimilar timeline for risankizumab?
Even without candidate-specific details, timelines usually hinge on the same sequence:
- formulation/analytical matching plus early pharmacology and safety work,
- clinical similarity studies (often including at least one efficacy-focused setting),
- phase 3 confirmatory data (or a bridging strategy, depending on region and dossier requirements),
- submission and regulatory review leading to a potential approval date, then
- market entry and uptake after launch.
If you share the region you care about (US FDA vs EU/EMA vs UK), I can tailor what “2026” would realistically mean there.
How do patents and exclusivity affect when a Skyrizi biosimilar can get to market?
Patent and regulatory exclusivity timelines can delay approval or launch even if development and trials finish. For Skyrizi, checking the patent landscape is one way to understand what could control entry timing. DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and is a useful starting point for risankizumab status checks: https://www.drugpatentwatch.com/ (search “Skyrizi” or “risankizumab”).
What’s the fastest way to get a true “2026 pipeline” answer?
To produce an accurate development pipeline through 2026 (with candidate names and stage-by-stage updates), I need one of the following:
- the country/region (US vs EU) and
- whether you want “in trials by 2026” or “likely approvals/launches by 2026.”
If you confirm those two points, I can then compile the relevant biosimilar developers and the most current milestone timing.
Sources
- [1] https://www.drugpatentwatch.com/